Clinical and Economic Aspects of Prophylaxis and Treatment of Pneumocystis carinii Pneumonia
- 1 February 1995
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 7 (2) , 95-98
- https://doi.org/10.2165/00019053-199507020-00001
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Two Controlled Trials of Rifabutin Prophylaxis against Mycobacterium avium Complex Infection in AIDSNew England Journal of Medicine, 1993
- Comparison of Atovaquone (566C80) with Trimethoprim-Sulfamethoxazole to Treat Pneumocystis carinii Pneumonia in Patients with AIDSNew England Journal of Medicine, 1993
- A Controlled Trial of Aerosolized Pentamidine or Trimethoprim–Sulfamethoxazole as Primary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1992
- A Controlled Study of Inhaled Pentamidine for Primary Prevention ofPneumocystis cariniiPneumoniaNew England Journal of Medicine, 1991
- Dapsone as a single agent is suboptimal therapy for Pneumocystis carinii pneumonia.1991
- A Controlled Trial of Early Adjunctive Treatment with Corticosteroids forPneumocystis cariniiPneumonia in the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1990
- Prevention of Pneumocystis carinii pneumonitis in AIDS patients with weekly dapsone.1990
- Aerosolized Pentamidine for Prophylaxis againstPneumocystis cariniiPneumoniaNew England Journal of Medicine, 1990
- Intravenous or Inhaled Pentamidine for TreatingPneumocystis cariniiPneumonia in AIDSAnnals of Internal Medicine, 1990
- The Risk ofPneumocystis cariniiPneumonia among Men Infected with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1990